Uncategorized
Preliminary CRISPR-Based HIV Treatment Study Shows Limited Success
CRISPR, HIV, gene editing, treatment, study, curative potential, early study, limited success
Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review
Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay
Maze Therapeutics Secures New Partnership for Pompe Drug Development After Sanofi Deal Collapse
Maze Therapeutics, Pompe drug, partnership, Sanofi deal collapse, drug development, genetic diseases
Duchenne Muscular Dystrophy: Potential Inclusion in Newborn Screening Programs
Duchenne muscular dystrophy, newborn screening, medical experts, decision-making, early diagnosis, treatment options.
Revolutionizing Healthcare: Streamlining Cell and Gene Therapy Manufacturing (Part 1)
Cell therapy, gene therapy, manufacturing, biotechnology, healthcare innovation, personalized medicine, production challenges, regulatory compliance, scalability, cost-effectiveness.
Shionogi Acquires Maze’s Pompe Disease Drug Following FTC’s Sanofi Deal Halt
Shionogi, Maze, Pompe disease, drug acquisition, FTC, Sanofi, $150 million
Revolutionizing Medicine: The Evolution and Future of Cell and Gene Therapy Manufacturing
Cell therapy manufacturing, gene therapy manufacturing, biomanufacturing, advanced therapies, CAR-T cell therapy, stem cell therapy, viral vectors, bioreactors, automation, scale-up, regulatory compliance, personalized medicine.
Moderna’s RSV Vaccine Decision Postponed by FDA to Late May
FDA, Moderna, RSV vaccine, decision, delay, May
MacroGenics Reviews Safety Protocols Following Three Patient Deaths in Prostate Cancer Drug Trial
MacroGenics, Phase 2 trial, prostate cancer, patient deaths, safety review, margetuximab, bispecific antibody
Sanofi Invests $500M in Novavax’s Covid Vaccine, Exploring Commercialization and Flu Combination
Sanofi, Novavax, Covid vaccine, commercialization, flu combination, $500M investment